期刊
NANO LETTERS
卷 22, 期 17, 页码 7220-7229出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.2c02724
关键词
immune cocktail therapy; transcytosis; spatiotemporally responsive; tumor adaptive resistance
类别
资金
- National Key Research and Development Program of China [2021YFB3800900]
- National Natural Science Foundation of China [51925305, 51873208, 51833010, 51803210, 51973217]
The immune checkpoint blockade (ICB) has a low response rate in clinical cancer treatment. Chemotherapy can enhance the response rate of the ICB, but it leads to side effects. Loading chemotherapy drugs through nanocarriers can reduce off-target toxicity. In this study, researchers developed doxorubicin (DOX) nanoparticles (DOX NPs) loaded in a polymeric carrier that was responsive to the tumor microenvironment (TME). However, a combination therapy of DOX NPs and ICB induced tumor adaptive resistance, which was found to be caused by TGF-beta 1. To overcome this resistance, an immune cocktail therapy containing DOX NPs, ICB, and TGF-beta 1 gene silencing nanoparticles was developed, successfully reversing the immunosuppressive TME and improving tumor treatment efficiency.
The immune checkpoint blockade (ICB) faces a low response rate in clinical cancer treatment. Chemotherapy could enhance the response rate of the ICB, but patients would suffer from side effects. The off-target toxicity could be reduced by loading the chemotherapeutic agent through nanocarriers. There-fore, we developed a polymeric carrier for doxorubicin (DOX) loading to form DOX nanoparticles (DOX NPs), which were spatiotemporally responsive to the tumor microenvironment (TME). DOX NPs had an efficient transcytosis property for deep tumor infiltration and sustained drug release ability. Unfortunately, a binary therapy of DOX NPs and ICB induces tumor adaptive resistance and causes dynamic deterioration of the TME. We propose for the first time that TGF-beta 1 is a major cause of tumor adaptive resistance and developed an immune cocktail therapy containing DOX NPs, ICB, and TGF-beta 1 gene silencing nanoparticles. This therapy successfully overcame tumor adaptive resistance by reversing the immunosuppressive TME and achieved enhanced tumor treatment efficiency.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据